United Therapeutics Corporation
Tyvaso
idiopathic pulmonary fibrosis
Date
TBD
FDA decision · Date TBD estimated
What's at stake
The FDA's approval decision on Tyvaso for idiopathic pulmonary fibrosis is due Date TBD. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 13h ago
“United Therapeutics plans to seek priority review of a supplemental New Drug Application to be submitted to the FDA by the end of this summer.”